Efficiency Of Antibody Biomedical Enterprises Based On SBM-DEA Model

The advent of the bio-economic era represents that China’s bio-pharmaceutical industry has entered a period of rapid development.As an emerging market of bio-pharmaceutical industry,antibody drugs have a late start but develop rapidly.At present,the antibody drugs in biological medicine market scale growth to occupy the first place,the development of antibody drugs made many drug companies both at home and abroad the main research content.The market of antibody drugs is exploding,and the number of biomedical enterprises involved in the research and development of antibody drugs is increasing,which occupies an important position in the biomedical industry.However,there are few researches on antibody biopharmaceutical enterprises at present.Through analyzing the current situation of antibody biopharmaceutical enterprises,this paper finds that there are still many problems in the research and development and operation of antibody biopharmaceutical enterprises.Based on the analysis of the problems existing in antibody biomedical enterprises,this paper found that R&D and operation are the core competitive links for the long-term development of antibody biomedical enterprises,and its efficiency research is worthy of enterprises’ attention and attention.Therefore,based on SBM-DEA model,this paper constructed the input-output index system of antibody biomedical enterprises.This paper analyzes the efficiency of antibody biopharmaceutical enterprises from the perspective of R&D and operation.This article first analyzes the antibody efficiency status quo of biological pharmaceutical enterprises,find out the problems existing in the enterprise,studies show that antibodies biological pharmaceutical enterprise in our country do not have a high level of innovation,and development of homogeneity is relatively serious,industry monopoly phenomenon at the same time,in view of the enterprise innovation level is not high and the problem of the unreasonable resources disposition,The efficiency of antibody biomedical enterprises was studied from two directions of R&D and operation.In the enterprise development direction,in order to guarantee the accuracy of the R&D efficiency in this paper,the selection/PD-L1 targets of research and development of PD-1 antibodies biological pharmaceutical enterprise as the research object,this paper build antibodies biological pharmaceutical enterprise of input and output index system,government spending as environment variables,introduced at the same time,adjust the government subsidies to the environmental factors to input indicators,Malmquist index was used to analyze the R&D efficiency of antibody biomedical enterprises from static and dynamic aspects.The results show that the technological efficiency of some enterprises has not reached the best state due to the influence of scale efficiency,which indicates that the R&D efficiency of most enterprises still has room for improvement.In the direction of operating efficiency,this paper analyzes the operating efficiency of antibody biomedical enterprises by using the superefficiency SBM-DEA model and Malmquist index.The research shows that the antibody biopharmaceutics enterprises with large PD-1/PD-L1 target are in a state of diminishing returns to scale,while small enterprises are in a state of increasing returns to scale.Finally,this paper conducts empirical analysis and research on the operating efficiency of antibody biomedicine enterprises based on SBM-DEA model,and constructs Tobit regression model to verify the influencing factors of enterprise operating efficiency.The results show that enterprise size,listing years and number of R&D personnel have a significant positive impact on the operating efficiency of antibody biomedical enterprises,while ownership concentration has no significant effect on the operating efficiency of enterprises.Through the research on R&D and operational efficiency of antibody biomedical enterprises,the problems existing in the efficiency of antibody biomedical enterprises are effectively analyzed.Finally,this paper proposes that antibody biomedical enterprises should improve their efficiency by absorbing and transforming innovative technological achievements,expanding the scale of R&D personnel,optimizing resource allocation and paying attention to large-scale development.The research results of this paper provide help for the antibody biomedical enterprises to improve their own research and development and operation efficiency and enhance their competitiveness in the antibody drug market.